FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785218974> ?p ?o ?g. }

• W2785218974 endingPage "1300" @default.
• W2785218974 startingPage "1293" @default.
• W2785218974 abstract "Cyclosporine has shown promising results for mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. However, available studies included only a small number of patients and did not include a validated and homogenous control group. We present the results from a retrospective monocentric study including 174 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis during 2005–2016. Among them, 95 received cyclosporine (3 mg/kg/day) plus supportive care, and 79 received supportive care only. Both a traditional exposed/unexposed method and a propensity score-matching method were used to compare the progression of skin detachment between day 0 and day 5, the proportion of patients with cutaneous re-epithelialization starting on day 5 or mucosal re-epithelialization on day 10, the duration of progression, and the number of deaths between the two groups. None of these outcomes significantly favored cyclosporine, either by the exposed/unexposed method or the propensity score method. Acute renal failure affected more patients receiving cyclosporine (P = 0.05). Overall, the results of this epidemiological study did not show a beneficial effect of cyclosporine in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. They are discordant with those previously published. The large number of patients and the use of a propensity score method provide valuable insights. The main limitation of the study is the lack of randomization. Cyclosporine has shown promising results for mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. However, available studies included only a small number of patients and did not include a validated and homogenous control group. We present the results from a retrospective monocentric study including 174 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis during 2005–2016. Among them, 95 received cyclosporine (3 mg/kg/day) plus supportive care, and 79 received supportive care only. Both a traditional exposed/unexposed method and a propensity score-matching method were used to compare the progression of skin detachment between day 0 and day 5, the proportion of patients with cutaneous re-epithelialization starting on day 5 or mucosal re-epithelialization on day 10, the duration of progression, and the number of deaths between the two groups. None of these outcomes significantly favored cyclosporine, either by the exposed/unexposed method or the propensity score method. Acute renal failure affected more patients receiving cyclosporine (P = 0.05). Overall, the results of this epidemiological study did not show a beneficial effect of cyclosporine in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. They are discordant with those previously published. The large number of patients and the use of a propensity score method provide valuable insights. The main limitation of the study is the lack of randomization." @default.
• W2785218974 created "2018-02-02" @default.
• W2785218974 creator A5002307250 @default.
• W2785218974 creator A5021773479 @default.
• W2785218974 creator A5022664611 @default.
• W2785218974 creator A5024835115 @default.
• W2785218974 creator A5027071137 @default.
• W2785218974 creator A5027409633 @default.
• W2785218974 creator A5029037831 @default.
• W2785218974 creator A5033205088 @default.
• W2785218974 creator A5045685914 @default.
• W2785218974 creator A5057668291 @default.
• W2785218974 creator A5063177685 @default.
• W2785218974 creator A5075840877 @default.
• W2785218974 creator A5078564033 @default.
• W2785218974 creator A5081578833 @default.
• W2785218974 creator A5086301152 @default.
• W2785218974 date "2018-06-01" @default.
• W2785218974 modified "2023-10-18" @default.
• W2785218974 title "Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients—Exposed/Unexposed and Propensity Score-Matched Analyses" @default.
• W2785218974 cites W1902133606 @default.
• W2785218974 cites W1919898452 @default.
• W2785218974 cites W1979259860 @default.
• W2785218974 cites W1990250054 @default.
• W2785218974 cites W1999717937 @default.
• W2785218974 cites W2012188315 @default.
• W2785218974 cites W2014048895 @default.
• W2785218974 cites W2025598475 @default.
• W2785218974 cites W2031125773 @default.
• W2785218974 cites W2045391651 @default.
• W2785218974 cites W2065082680 @default.
• W2785218974 cites W2083536638 @default.
• W2785218974 cites W2101695930 @default.
• W2785218974 cites W2109696646 @default.
• W2785218974 cites W2136481244 @default.
• W2785218974 cites W2221798782 @default.
• W2785218974 cites W2327541450 @default.
• W2785218974 cites W2527798119 @default.
• W2785218974 cites W2554810510 @default.
• W2785218974 cites W2562973023 @default.
• W2785218974 cites W2588690268 @default.
• W2785218974 cites W2598958138 @default.
• W2785218974 cites W2611564992 @default.
• W2785218974 cites W2626895392 @default.
• W2785218974 doi "https://doi.org/10.1016/j.jid.2017.12.034" @default.
• W2785218974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29369774" @default.
• W2785218974 hasPublicationYear "2018" @default.
• W2785218974 type Work @default.
• W2785218974 sameAs 2785218974 @default.
• W2785218974 citedByCount "36" @default.
• W2785218974 countsByYear W27852189742018 @default.
• W2785218974 countsByYear W27852189742019 @default.
• W2785218974 countsByYear W27852189742020 @default.
• W2785218974 countsByYear W27852189742021 @default.
• W2785218974 countsByYear W27852189742022 @default.
• W2785218974 countsByYear W27852189742023 @default.
• W2785218974 crossrefType "journal-article" @default.
• W2785218974 hasAuthorship W2785218974A5002307250 @default.
• W2785218974 hasAuthorship W2785218974A5021773479 @default.
• W2785218974 hasAuthorship W2785218974A5022664611 @default.
• W2785218974 hasAuthorship W2785218974A5024835115 @default.
• W2785218974 hasAuthorship W2785218974A5027071137 @default.
• W2785218974 hasAuthorship W2785218974A5027409633 @default.
• W2785218974 hasAuthorship W2785218974A5029037831 @default.
• W2785218974 hasAuthorship W2785218974A5033205088 @default.
• W2785218974 hasAuthorship W2785218974A5045685914 @default.
• W2785218974 hasAuthorship W2785218974A5057668291 @default.
• W2785218974 hasAuthorship W2785218974A5063177685 @default.
• W2785218974 hasAuthorship W2785218974A5075840877 @default.
• W2785218974 hasAuthorship W2785218974A5078564033 @default.
• W2785218974 hasAuthorship W2785218974A5081578833 @default.
• W2785218974 hasAuthorship W2785218974A5086301152 @default.
• W2785218974 hasBestOaLocation W27852189741 @default.
• W2785218974 hasConcept C126322002 @default.
• W2785218974 hasConcept C141071460 @default.
• W2785218974 hasConcept C16005928 @default.
• W2785218974 hasConcept C167135981 @default.
• W2785218974 hasConcept C17923572 @default.
• W2785218974 hasConcept C204243189 @default.
• W2785218974 hasConcept C2780664588 @default.
• W2785218974 hasConcept C535046627 @default.
• W2785218974 hasConcept C71924100 @default.
• W2785218974 hasConcept C72563966 @default.
• W2785218974 hasConceptScore W2785218974C126322002 @default.
• W2785218974 hasConceptScore W2785218974C141071460 @default.
• W2785218974 hasConceptScore W2785218974C16005928 @default.
• W2785218974 hasConceptScore W2785218974C167135981 @default.
• W2785218974 hasConceptScore W2785218974C17923572 @default.
• W2785218974 hasConceptScore W2785218974C204243189 @default.
• W2785218974 hasConceptScore W2785218974C2780664588 @default.
• W2785218974 hasConceptScore W2785218974C535046627 @default.
• W2785218974 hasConceptScore W2785218974C71924100 @default.
• W2785218974 hasConceptScore W2785218974C72563966 @default.
• W2785218974 hasIssue "6" @default.
• W2785218974 hasLocation W27852189741 @default.
• W2785218974 hasLocation W27852189742 @default.
• W2785218974 hasLocation W27852189743 @default.
• W2785218974 hasLocation W27852189744 @default.

• next